The ability of erythromycin A base to penetrate and accumulate in tissue culture cells of human origin was investigated. The antibiotic was highly concentrated by early passage ceUls of normal bronchus, kidney, liver, lung, and skin and by cancer ceUs derived from breast, liver, and lung. Intracellular levels 4 to 12 times that of the extracellular milieu were obtained in both early-passage and transformed cells. The total quantity of erythromycin accumulated depended on the extracellular concentration of antibiotic, but the cellular/ extracellular ratios were, for the most part, independent of the initial extracellular drug concentration. In all cell types tested, the accumulated antibiotic rapidly egressed when cells were incubated in antibiotic-free medium. Bioactivity assays demonstrated that the expelled drug was unmetabolized, fully active antibiotic. The concentration of erythromycin by a variety of human cell types probably accounts, in part, for the effectiveness of the antibiotic against intracellular parasites such as Legionella and Chlamydia spp.
Erythromycin has been widely, successfully, and safely used for over two decades as treatment for infections caused by susceptible pathogens. Although erythromycin has been recognized as an effective drug, investigators have been puzzled by the low and unpredictable levels in plasma that are usually observed after administration of the antibiotic. The paucity of drug in the vasa may be due to tissue accumulation, since distribution studies on tissue samples excised from dogs (14) and rats (15) have shown that erythromycin is concentrated well above blood levels in organs such as the liver, spleen, kidney, lung, and pancreas and in submaxillary and adrenal glands.
Infections attributed to Legionella spp., which are facultative intracellular bacteria, and Chlamydia spp., which are obligate intracellular parasites, are effectively treated with erythromycin (1) . Both organisms are known to parasitize a large number of human cell types. The ability of erythromycin to control these organisms suggests that the antibiotic penetrates and exerts its action within the invaded host cell. Indeed, recent studies have shown that both human polymorphonuclear leukocytes (PMNs) (20, 23) and alveolar macrophages (8, 12) accumulate erythromycin at 15 to 24 times extracellular levels. Further, studies have shown that erythromycin assists human PMNs (20) and cultured guinea pig peritoneal macrophages (28) in the killing of phagocytosed Legionella pneumophila. All the foregoing indicates that erythromycin may be concentrated intracellularly by eukaryotic cells and suggests that this accumulation may be responsible for the aberrant levels in plasma usually observed after antibiotic administration.
The results presented in this study demonstrate that a variety of types of human tissue culture cells sequester erythromycin. We suspect that, after erythromycin intake, certain mammalian tissues serve as drug reservoirs which vastly influence antibiotic pharmacokinetics and bioactivity. We suggest that in cases in which an antibiotic is significantly accumulated and released by host cells, the traditional measurement of drug levels in serum (12) . The cell volume of each cell suspension was determined with tritiated water, and the intracellular/extracellular distribution of antibiotic, expressed as the C/E ratio, was calculated (12) .
The ability of cells to actively concentrate erythromycin was further evaluated with Formalin-killed cells. The cells were killed by treating a suspension (ca. 5 x 106 cells per ml) in growth medium minus FBS with 10% Formalin at 37°C for 30 min. The dead cells were sedimented, washed twice with growth medium, and resuspended to the original density in growth medium.
Measurement of egress of erythromycin. Egress of erythromycin was determined after incubation of the test cells in growth medium containing radiolabeled antibiotic for the time period indicated. After erythromycin accumulation, the cells were rapidly centrifuged and resuspended in prewarmed, antibiotic-free growth medium. The egress of erythromycin at the indicated times were determined by the velocity gradient technique described above.
Bioactivity of egressed erythromycin. The test cell suspensions (ca. 5 x 106 cells per ml) were allowed to accumulate erythromycin by incubation with rotary agitation (150 rpm) for 2 h at 37°C in growth medium containing 10 mg of [3H]erythromycin A base per liter. The cells were sedimented by centrifugation and resuspended in prewarmed 0.1 M potassium phosphate buffer (pH 8.0). Incubation was then continued for 2 h at 37°C with rotary shaking (150 rpm). The cells were sedimented by centrifugation, and the radioactivity and bioactivity (agar diffusion assay against Sarcina luteus ATCC 9341 on Difco medium no. 11 with erythromycin A base dihydrate as the standard) of the supernatant was determined. The specific activity of the effluxed erythromycin was compared with that of the antibiotic before its incubation with the test cells. RESULTS The accumulation of erythromycin by various human-derived tissue culture cells is shown in Table 1 . Both normal early-passage cells and continuous cancer line cells sequestered erythromycin at levels several-fold higher than external concentrations. Of the cell types tested, the highest accumulation occurred in early-passage foreskin cells, for which a C/E ratio of 12 was attained upon exposure to 10 mg of antibiotic per liter. Most of the cell types accumulated erythromycin at six to nine times the extracellular concentration, although normal liver and cancer liver cells gave lower values. Although the cells were incubated in the presence of [3H]erythromycin for 2 h, most of the intracellular accumulation occurred during the first hour of exposure. All cell types treated with 2 to 20 mg of erythromycin per liter maintained -90% viability during the course of the incubation period.
In all cell types examined, the total quantity of erythromycin accumulated depended on the extracellular concentration of antibiotic. Although some slight differences in C/E ratios were observed when the extracellular antibiotic concentrations were varied, the disparity was less than 20% at the levels of erythromycin tested (2 to 10 mg/liter) after 1 h of accumulation. In most cases, higher initial concentrations of erythromycin gave slightly higher C/E ratios, although in some cell types there was virtually no difference between the C/E ratios obtained with varied initial drug concentrations. Cancer liver and lung cells were the only exceptions noted to the above. In these cell types, slightly lower C/E ratios were consistently observed as the initial extracellular antibiotic level was increased (Table 1) .
When cells that had accumulated erythromycin were transferred to antibiotic-free medium, rapid egress of the VOL. 27, 1985 on July 5, 2017 by guest http://aac.asm.org/ Downloaded from intracellular erythromycin occurred ( Fig. 1 and Table 1 ). The rate of efflux usually reflected the kinetics of accumulation. Cells which rapidly concentrated antibiotic lost drug at a similar rate when the external milieu was replaced with antibiotic-free medium (Fig. 1) . When cells accumulated erythromycin at a diminished rate, the kinetics of efflux were slower than in cells which rapidly concentrated antibiotic. In cells which rapidly accumulated antibiotic, egress continued until equilibrium was again established.
The (Fig. 1) . Similar efflux kinetics were observed for all cell types tested. These data suggest that intracellularly concentrated erythromycin is not tightly bound to cellular components.
Cells held at 4°C did not accumulate or bind antibiotic (Table 2 ) or allow egress of previously concentrated eryth- (14) and rats (15) with 14C-labeled erythromycin have indicated that the antibiotic is concentrated in liver, spleen, kidney, lungs, pancreas, and submaxillary and adrenal glands at levels significantly above those in plasma. With a noninvasive procedure, a more recent study (27) in which 11C-labeled erythromycin and positron emission tomography were used has shown that erythromycin rapidly penetrates and concentrates in human pulmonary tissue. These studies demonstrate that erythromycin accumulates in mammalian tissues at concentrations above levels in plasma, but the techniques used did not allow differentiation between intracellularly accumulated drug and antibiotic loaded in interstitial and other extravascular compartments.
The data presented here, showing the in vitro uptake and intracellular accumulation of erythromycin by a variety of human-derived tissue culture cells, strongly suggest that a similar concentration phenomenon occurs in mammalian tissues after antibiotic administration. Although anomalies associated with cells grown in tissue culture must be consid- ered, the marked accumulation by several types of normal, early-passage cells lends further credence to this thesis. Our findings suggest that mammalian organs and tissues, upon exposure to erythromycin, accumulate an intracellular reservoir of antibiotic from the vasa. In consonance with the tissue culture cell data, this reservoir of sequestered erythromycin would readily egress from the intracellular compartments as the extracellular level of antibiotic diminished. The released erythromycin would be unmetabolized, unaltered, fully active antibiotic. Although the efficacy of erythromycin against a variety of infections caused by susceptible organisms has been demonstrated (1), the low and erratic levels in plasma that are usually observed after antibiotic intake has often concerned many clinicians. The blood level, however, is only one factor which must be considered when selecting an appropriate antibiotic therapy. To our knowledge, the concentration of erythromycin in plasma that is associated with therapeutic success has not been established, but the ability of the antibiotic to penetrate, accumulate, and exit eukaryotic cells must have both pharmacokinetic and antibacterial implications. We suspect that the extravascular localization of erythromycin may be more pertinent to the clinical efficacy, at least with some types of infection, than the actual levels in plasma, since active drug at the site of sepsis is the most important consideration.
For example, there is abundant evidence that some microorganisms survive or proliferate after phagocytosis by human cells (3, 10, 11, 13, 22) . This frustration of the normal phagocytic-killing process must be of paramount importance in cases of persistent or relapsed infections. The intracellular location of the engulfed organisms protects them from antibiotics that are unable to penetrate and exert their action. In these cases, after termination of antibiotic therapy, the protected, intracellular organism may again fulminate into a renewed infection. The ability of erythromycin to penetrate and accumulate in a variety of eukaryotic cell types may prevent survival of sensitive phagocytosed organisms, thereby exerting profound effects on the course of an infection.
Phagocytosis, which is the ingestion of any particulate matter (e.g., bacteria) by cells, is common to all nucleated eukaryotic cells (4) and is not limited to leukocytes. Nucleated eukaryotic cells can be classified as either professional phagocytes (PMNs, monocytes, and tissue macrophages) or VOL. 27, 1985 on July 5, 2017 by guest http://aac.asm.org/ Downloaded from nonprofessional phagocytes (e.g., fibroblasts). The former group of cells normally circulates via the circulatory system and constitutes the cellular host defense; the latter group is usually fixed and does not circulate. Although the extent of cellular killing and the role of these latter cells in host defense remains obscure and undefined, nonprofessional phagocytes may influence the course of an infection.
Erythromycin, which is the antibiotic of choice for the treatment of Legionnaires disease (1) , is thought to owe much of its effectiveness to its ability to penetrate, accumulate, and inhibit L. pneumophila ingested by PMNs (20) . Legionnaires disease was first considered to be exclusively a pneumonic illness, and the intracellular nature of the infecting bacilli has been demonstrated in lung tissue. It is now clear that, in many hosts, the causative organism disseminates to extrathoracic organs. In some instances, infection without pulmonary involvement also occurs (18, 19) . Biochemical abnormalities and direct-immunofluorescence techniques have revealed that the liver (24), spleen (25) , kidney (25) , peripheral lymph nodes (25) , bone marrow (9, 25), brain (7), myocardium (26) , and intestine (5) may be invaded. Direct evidence for the extrapulmonary involvement was confirmed when intracellular Legionella bacilli were demonstrated in liver sinusoidal lining cells (24) and kidney mesangial and endothelial cells (25) by electron microscopy.
The (17) . Although epithelial cells may be the primary host of C. trachomatis (21) , the plethora of recognized and suspected clinical conditions suggests that these organisms are capable of invading a variety of cell types. Antibiotic therapy for chlamydioses usually consists of appropriate dosages of either erythromycin or tetracycline (1, 2) . This suggests that these two antibiotics reach intracellular therapeutic levels in infected cells. Both antibiotics are known to penetrate and accumulate in human PMNs and alveolar macrophages (8, 20, 23) . The ability of erythromycin to suppress Chlamydia infections further supports the thesis that the antibiotic penetrates and accumulates in a variety of human cell types in vivo.
In conclusion, this study indicates that erythromycin is highly concentrated by a variety of eukaryotic cell types, and it seems likely that this intracellular drug reservoir must be of clinical importance. For many years a great deal of attention has been focused on obtaining erythromycin formulations which give predictably high and sustained antibiotic levels in plasma. These 
